This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT05298306 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Lateral Pharma Pty Ltd |
| Enrollment | 26 participants |
| Design | Interventional, Randomized, Crossover, Masking: Quadruple |
| Conditions | Radiculopathy Lumbar |
| Interventions | LAT8881; Placebo |
| Start | May 17, 2022 |
| Primary completion | May 12, 2023 |
| Study completion | Jun 16, 2023 |
| Results posted | Yes, in the registry |
| Registry last updated | Nov 27, 2024 |
| Collaborators | Southern Star Research |
Compounds on this site that cite this trial
What the registry says the trial is about
The study consists of two parts. Part A will evaluate the safety and tolerability of intravenous LAT8881 in healthy volunteers using an ascending dose schedule. Part B will evaluate the analgesic efficacy of a single intravenous dose of LAT8881, compared with placebo, in patients with lumbar radicular pain.
Healthy volunteers are not accepted for Part B.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| The Number of Participants With Adverse Events by Dose (Part A) | From first dose of LAT8881 to end of study visit (Day 14) |
| Change in Baseline Pain With Intravenous LAT8881 in Patients With Lumbar Radicular Pain (Part B) | From start of infusion to 6 hours after start of infusion |
6 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
